4.7 Article

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial

Related references

Note: Only part of the references are listed.
Article Medicine, General & Internal

Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin A Randomized Trial

John P. H. Wilding et al.

ANNALS OF INTERNAL MEDICINE (2012)

Review Biotechnology & Applied Microbiology

SGLT2 inhibition - a novel strategy for diabetes treatment

Edward C. Chao et al.

NATURE REVIEWS DRUG DISCOVERY (2010)

Article Pharmacology & Pharmacy

Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

B. Komoroski et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)

Article Endocrinology & Metabolism

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

James F. List et al.

DIABETES CARE (2009)

Editorial Material Medicine, General & Internal

Rosiglitazone no longer recommended

[Anonymous]

LANCET (2008)

Article Mathematical & Computational Biology

Covariate adjustment for two-sample treatment comparisons in randomized clinical trials: A principled yet flexible approach

Anastasios A. Tsiatis et al.

STATISTICS IN MEDICINE (2008)

Review Medicine, Research & Experimental

Islet β cell failure in type 2 diabetes

Marc Prentki et al.

JOURNAL OF CLINICAL INVESTIGATION (2006)